Key result
Lower serum omentin-1 in obese patients correlates with reduced FMD.
Case-Control (n=95)
Lower serum omentin-1 levels are associated with decreased flow-mediated dilation, suggesting it may serve as an early marker of endothelial dysfunction in obese patients.
Answers are grounded in this paper and cite their sources.
Omentin-1 may mark endothelial dysfunction in obesity; hypothesis-generating and requires prospective validation before clinical use.
INTRODUCTION: Our aim was to investigate the relationship between serum omentin-1 levels and endothelial dysfunction in obese patients. MATERIAL AND METHODS: We evaluated 50 obese patients, and age/gender matched 45 healthy non-obese subjects as controls. Oral glucose tolerance test, lipid parameters, uric acid levels, homeostatic model assessment-insulin resistance (HOMA-IR) index, serum omentin-1 levels and flow mediated dilatation (FMD) % were measured in all subjects. Body compositions were analyzed with bioelectrical impedance method using a Tanita Body Composition Analyzer and ViScan. RESULTS: Serum omentin-1 levels were found significantly lower in obese population compared to the control subjects. FMD response was significantly decreased in obese population. There was a significant positive correlation between serum omentin-1 levels and FMD response (r=0.359, p<0.001). Serum omentin-1 levels were negatively correlated with body mass index (BMI), waist circumference, total fat percentage, visceral fat, fasting insulin and HOMA-IR index. CONCLUSION: Lower serum omentin-1 levels and decreased FMD response may be an early marker of endothelial dysfunction in obese patients.
No takes yet. Share an insight, caveat, or question.
Ayla Özaydoğdu Çimen (2017) conducted a case-control in Obesity (n=95). Obesity vs. Healthy non-obese subjects was evaluated on Correlation between serum omentin-1 levels and flow mediated dilatation (FMD) response (r=0.359, p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: